scholarly journals Radiolabelled Peptides for Positron Emission Tomography and Endoradiotherapy in Oncology

2020 ◽  
Vol 13 (2) ◽  
pp. 22 ◽  
Author(s):  
Christine Rangger ◽  
Roland Haubner
Keyword(s):  
Positron Emission Tomography ◽  
Clinical Trials ◽  
Metabolic Stability ◽  
Emission Tomography ◽  
Clinical Routine ◽  
Peptide Receptor ◽  
Radiolabelled Peptides ◽  
Positron Emission ◽  
Pros And Cons

This review deals with the development of peptide-based radiopharmaceuticals for the use with positron emission tomography and peptide receptor radiotherapy. It discusses the pros and cons of this class of radiopharmaceuticals as well as the different labelling strategies, and summarises approaches to optimise metabolic stability. Additionally, it presents different target structures and addresses corresponding tracers, which are already used in clinical routine or are being investigated in clinical trials.

scholarly journals Positron Emission Tomography Imaging of the Gastrin-Releasing Peptide Receptor with a Novel Bombesin Analogue

ACS Omega ◽  
2019 ◽  
Vol 4 (1) ◽  
pp. 1470-1478 ◽  
Author(s):  
Joseph Lau ◽  
Etienne Rousseau ◽  
Zhengxing Zhang ◽  
Carlos F. Uribe ◽  
Hsiou-Ting Kuo ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Positron Emission Tomography Imaging ◽  
Emission Tomography ◽  
Tomography Imaging ◽  
Peptide Receptor ◽  
Gastrin Releasing Peptide ◽  
Positron Emission

scholarly journals Positron Emission Tomography (PET) Imaging of Prostate Cancer with a Gastrin Releasing Peptide Receptor Antagonist - from Mice to Men

Theranostics ◽  
2014 ◽  
Vol 4 (4) ◽  
pp. 412-419 ◽  
Author(s):  
Gesche Wieser ◽  
Rosalba Mansi ◽  
Anca L. Grosu ◽  
Wolfgang Schultze-Seemann ◽  
Rebecca A. Dumont-Walter ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Positron Emission Tomography ◽  
Receptor Antagonist ◽  
Pet Imaging ◽  
Emission Tomography ◽  
Peptide Receptor ◽  
Gastrin Releasing Peptide ◽  
Positron Emission

scholarly journals Infection Dynamics and Response to Chemotherapy in a Rabbit Model of Tuberculosis using [18F]2-Fluoro-Deoxy-d-Glucose Positron Emission Tomography and Computed Tomography

2012 ◽  
Vol 56 (8) ◽  
pp. 4391-4402 ◽  
Author(s):  
Laura E. Via ◽  
Dan Schimel ◽  
Danielle M. Weiner ◽  
Veronique Dartois ◽  
Emmanuel Dayao ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Positron Emission Tomography ◽  
Clinical Trials ◽  
Bacterial Load ◽  
Rabbit Model ◽  
Emission Tomography ◽  
Lesion Volume ◽  
Total Lung Volume ◽  
Positron Emission ◽  
Response To Chemotherapy

ABSTRACTWith a host of new antitubercular chemotherapeutics in development, methods to assess the activity of these agents beyond mouse efficacy are needed to prioritize combinations for clinical trials. Lesions inMycobacterium tuberculosis-infected rabbits are hypoxic, with histopathologic features that closely resemble those of human tuberculous lesions. Using [18F]2-fluoro-deoxy-d-glucose ([18F]FDG) positron emission tomography–computed tomography (PET-CT) imaging, we studied the dynamics of tuberculosis infection in rabbits, revealing an initial inflammatory response followed by a consolidative chronic disease. Five weeks after infection, as much as 23% of total lung volume was abnormal, but this was contained and to some extent reversed naturally by 9 weeks. During development of this chronic state, individual lesions in the same animal had very different fates, ranging from complete resolution to significant progression. Lesions that remained through the initial stage showed an increase in volume and tissue density over time by CT. Initiation of chemotherapy using either isoniazid (INH) or rifampin (RIF) during chronic infection reduced bacterial load with quantitative changes in [18F]FDG uptake, lesion density and total lesion volume measured by CT. The [18F]FDG PET uptake in lesions was significantly reduced with as little as 1 week of treatment, while the volume and density of lesions changed more slowly. The results from this study suggest that rabbits may be a useful surrogate species for evaluating novel chemotherapies and understanding changes in both PET and CT scans in human clinical trials.

Sign in / Sign up

Export Citation Format

Share Document